

### Personal Infromation

Name, Surname	Zaza Avaliani
Date Of Birth	24-05-1960
Personal Number	010 030 095 80
Address	Tbilisi, Delisi Street N16
Telephone number	599 58 53 36
Mail	<u>avaliani.zaza@eu.edu.ge</u> / avalianizaza@yahoo.com

#### Education

Years	Name Of School	Specialty	Qualification
1978-1984	Tbilisi State Medical Institute	Faculty of Medicine	Academic degree of Physician
1984-1986	Tbilisi State Medical Institute	Abnormal anatomy	Residency
1998-2003	Tbilisi State Medical Institute	Abnormal anatomy	Doctor of Medical Sciences

## Work experience

Years	Organization	Position
2019 – Still	European University	Professor
Today		
2014 Still	National Center for Tuberculosis and Lung Diseases	Executive Director
Today		
2012-2014	Tbilisi Central Hospital	Head of Outpatient Service
2014 Still	Tbilisi Medical Academy	Invited Professor
Today		
2013-2014	Cancer Research Center	Abeloff Laboratory Chief
		Physician
2012- Still	Tbilisi Central Hospital	Head of the Department of
Today		Abnormal Anatomy
2012-2013	Clinic "Health Center"	Head of Project Administration



	CY	
2011	University of Georgia	Full professor
2011 Still Today	Clinic Network "GeoHospitals"	Pathologist Anatomy Department of Pathology
2009-2010	Tbilisi Vocational Education Center "Spectrum"	Director
2009-2012	Swiss International Development Science Project	Project Coordinator Methodology for Assessing Disabilities in the Disabled
2010-2012	Clinic "444"	Residency Course in Therapeutic Dentistry, Deputy Director
2007-2010	IB Euro-Caucasian University	Program Leader
2006-2008	Curatio Medical Consulting Group	Member of the Advisory Group
2002 Still Today	International Education Council	Member of the National Council of Bioethics
2007-2009	Aversi Clinic Ltd	Head of Strategic Development and Quality Service
2004-2005	Educational project "Socrates"  European Union Tbilisi, Georgia	EU Education Project "Socrates" Local Manager
2003-2006	Tbilisi State Medical Institute	Head of the Educational Science Department
1998-2003	Tbilisi State Medical Institute	Department Assistant / Associate Professor Department of Abnormal Anatomy
1998-2011	A. Aladashvili University Clinic	Department of Pathological Anatomy, Pathologist
1988-1998	National Center for Sepsis	Physician of the Department of Pathological Anatomy
1993-1998	National Center for Sepsis	Assistant Department of Pathological Anatomy
1986-1988	Medical Service of the Armed Forces of the Soviet Union	Senior Lieutenant

### Knowledge of a foreign language



Foreign Language	Beginning Level	Medium Level	Good Level	Very Good Level	Select if you have the appropriate certificate
ENGLISH			X		
RUSSIAN			X		

### Knowledge of office programs

	Beginning Level	Medium Level	Good Level	Very Good Level
Microsoft Office Word			X	
Microsoft Office Excel			X	
Microsoft Office			X	
PowerPoint				
Zoom				
google drive				
Other				

### Participation in advanced training courses, seminars, trainings

Nº	Year	Name of the training	Your status (facilitator, participant, organizer)
			participant, organizer)
	2020	OA-40-742-24 Co-morbidities and all-cause mortality	Advancing Prevention "The 51st
		post tuberculosis treatment: a retrospective cohort	Union World Conference On Lung
		study of patients previously treated with second-line	Health" 20-24 October 2020
1		tuberculosis drugs in Georgia A. Salindri,1 M. Kipiani,2	"Valencia, Spain. Online Event
		M. Gujabidze,3 N. Chumburidze, 3 N. Lomtadze,4 N.	
		Tukvadze,3 <b>Z. Avaliani</b> ,2 R. Kempker,5 H.	
		Blumberg,6,7 M. Magee,6,7	
	2020	TBs-OA-09 Association of delamanid concentrations	Advancing Prevention "The 51st
		with treatment outcomes or drug resistance among	Union World Conference On Lung
2		patients with mDR-TB D.S. Graciaa,1 M. Kipiani,2 L.	Health" 20-24 October 2020
		Mikiashvili,2 K. Barbakadze,2 N. Bablishvili,2 W.	"Valencia, Spain. Online Event
		Alghamdi,3 C. Peloquin,4 <b>Z. Avaliani</b> ,2 R. Kempker	
	2020	TBs-OA-09 Association of delamanid concentrations	Advancing Prevention "The 51st
		with treatment outcomes or drug resistance among	Union World Conference On Lung
3		patients with mDR-TB D.S. Graciaa,1 M. Kipiani,2 L.	Health" 20-24 October 2020
		Mikiashvili,2 K. Barbakadze,2 N. Bablishvili,2 W.	"Valencia, Spain. Online Event
		Alghamdi,3 C. Peloquin,4 <b>Z. Avaliani</b> ,2 R. Kempker	



# $\mathbf{CV}$

	07/30/201	TB ALLIANCE	Winner of the grant project
	8-	NCT03338621 Mikiashvili/Tukvadze (PI) Global Alliance	Co-researcher
	02/22/202	for TB Drug Development	Participant
4	2	Title: An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)"	
	2016-2021	Institute Germans Trias I Pujol Tukvadze (site PI)	Winner of the grant project
5	2010 2021	"Double-Blind, randomized, masked, placebo-controlled, Clinical Trial to Investigate the efficacy of the nutraceutical Nyadtum rasae administered to contact of active tuberculosis in the Republic of Georgia"  Co-Investigator	Co-researcher Participant
	2015-2020	NIH/NIAID Vashakidze (PI)	Winner of the grant project
	2013 2020	"Expanding global knowledge of tuberculosis by establishing the Georgia Tuberculosis Portal 2015-2020" National Institute of Allergy and Infectious Diseases	Co-researcher Participant
		Co-Investigator	
	2001-2025	ERC-2019-AdG Gagneux (PI), Tukvadze (Site PI)  Horizon 2020, the European Commission  Title: Linking Within-host and Between-Host Evolution in Multidrug-resistant Mycobacterium tuberculosis	Winner of the grant project Co-researcher Participant
		The goal of this project is to explore the causes and consequences of within-host evolution in multidrugresistant Mtb over time and across different body compartments, to look for potential trade-offs with between-host evolution during patient-to-patient transmission, and to define the role of suboptimal patient treatment and phenotypic drug tolerance on	



drug resistance evolution inside patients and across patient populations.	
Role: Co-Investigator	
DRTB-HDT Reither/Tukvadze (PI)  Horizon 2020, European Commission  Title: Stratified host-directed therapy for rifampicin- resistant TB: a randomized controlled multi-centre trial  The goal of this project will be to determine the efficacy, safety, and tolerability of two adjunctive host-directed therapies (HDTs) in patients with rifampicin-resistant (RIF-R) pulmonary tuberculosis in a multicenter international trial. The selected HDT candidates represent two complementary HDT strategies: reducing inflammation (CC-11050) vs inducing host cell anti- microbial activity (metformin).  Role: Co-Investigator	Winner of the grant project Co-researcher Participant
Horizon 2020, the European Commission  Title: A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy (HDT) in TB patients.  The goal of this project is toevaluate in a clinical trial the potential impact of aspirin (an anti-inflammatory HDT) as adjunct to standard therapy for drug sensitive (DS-) and MDR-TB.  Role: Co-Investigator	Winner of the grant project Co-researcher Participant
	patient populations. Role: Co-Investigator  DRTB-HDT Reither/Tukvadze (PI)  Horizon 2020, European Commission  Title: Stratified host-directed therapy for rifampicinresistant TB: a randomized controlled multi-centre trial  The goal of this project will be to determine the efficacy, safety, and tolerability of two adjunctive host-directed therapies (HDTs) in patients with rifampicin-resistant (RIF-R) pulmonary tuberculosis in a multicenter international trial. The selected HDT candidates represent two complementary HDT strategies: reducing inflammation (CC-11050) vs inducing host cell antimicrobial activity (metformin).  Role: Co-Investigator  SMA TB Tukvadze/Vashakidze (Site PIs)  Horizon 2020, the European Commission  Title: A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy (HDT) in TB patients.  The goal of this project is toevaluate in a clinical trial the potential impact of aspirin (an anti-inflammatory HDT) as adjunct to standard therapy for drug sensitive (DS-) and MDR-TB.

### Publication

Nº	Year	Name Of Publication	
1	2015	A comparison of the Xpert(®) MTB/RIF and GenoType(®)	
1		MTBDRplus assays in Georgia	



	1			
	2016	"Introduction of New Drugs for the Treatment of DR- TB as Part of	Good Practices in	
		Programme Management of M/XDR-TB in Georgia"	Strengthening Health	
			Systems for the	
			Prevention and Care of	
			Tuberculosis and Drug-	
2			resistant Tuberculosis,	
			WHO 2016, ISBN	
			9789289051293	
			Lomtadze N, Kiria N,	
			Nanava U, Avaliani Z.	
	2015	"High-dose vitamin D3 in adults with pulmonary tuberculosis: A	The American journal of	
		double blind, randomized, controlled trial"	Clinical Nutrition,	
			AJCN/2015/113886; First	
			published online	
			September 23, 2015"	
			Tukvadze N, Sanikidze E,	
			Kipiani M, Hebbar G,	
3			Easley KA, Shenvi N,	
			Kempker RR, Jennifer K.	
			Frediani, Mirtskhulava V,	
			Alvarez J, Lomtadze N,	
			Vashakidze L, Avaliani Z,	
			Hao L, Carlos Del Rio,	
			Tangpricha V, Blumberg	
			HM, Ziegler TR	
	2018-	Impact of adjuvant therapeutic surgery on the health-related quality	Pau Benito, Sergo	
	2020	of life of pulmonary tuberculosis patients"	Vashakidze, Shota	
			Gogishvili, Keti	
			Nikolaishvili, Albert	
4			Despuig, Nestan	
			Tukvadze, Natalia	
			Shubladze, <b>Zaza Avaliani</b> ,	
			Cristina Vilaplana	
			_	
	2020	ERJ Open Research 2020 6: 00083-2020; DOI:	Zaza Avaliani, Ogtay	
		10.1183/23120541.00083-2020	Gozalov, Giorgi	
			Kuchukhidze, Alena	
_			Skrahina, Viorel Soltan,	
5			Martin van den Boom,	
			Irina Vasilyeva, Valentina	
			Vilc, Askar Yedilbayev	
	ĺ			



		European	Respiratory
		Journal 2020	
	"Reactive lymph node hyperplasia	Manual	
6	Morphological evaluation criteria in different diseases and in experiments "		
	Author: Zaza Avaliani		
	Editor: Dinara Kasradze		

### Scientific Activities

Nº	Year	Name Of Scientific Activities	
1	2015- Present	TB Drug Resistance Reference Materials	Research coordinator
2	01/02/201631/07/2016	Xpert Ultra trial: Beta study Phase 1	Project Manager
3	2016- Present	Xpert Ultra trial: Beta study Phase 2	Project Manager
4	30/01/201531/10/16	Evaluation of efficacy of Plasma Cluster tecnology for	Project Director
		ensuring proper IC in TB Hospital	
5	2016- Present	"Pilot Study to estimate the potential efficacy and safety	Project Coordinator
		of using Adjunctive Ibuprofen fpr the treatment of XDR	
		Tuberculosis"	
6	2016- Present	Pharmacokinetics of second-line antituberculosis drugs	Researcher
		among patients with multidrug-resistant tuberculosis	
7	2009-2012	Disability Status Assessment project	Project coordinator
8	2014-present	Member of Phthisiologists and Pulmonologists	
		Association of Georgia	
9	2004 – 2009	Member of American Chamber of Commerce, Tbilisi,	
		Georgia	
10	2001 – 2004	Member of Board, Expert group on elaborating Georgian	
		Law of High Education, Tbilisi	
11	2005	Representative, Institutional evaluation project,	
		Association of European Universities	
12	2007 – Present	President, Association of Georgian Pathologists XXI,	
		Tbilisi, Georgia	
13	2006 – Present	President, Association of Medical Education	
		Professionals, Tbilisi, Georgia	
14	2005 – Present	Board member, Association of Georgian Clinical	
		Pathologists, Tbilisi, Georgia	
15	2002 – Present	Member, National Bioethics Council, Expert at Ministry	
		of Labor, Health and Social Affairs, Tbilisi, Georgia	
16	2001 – Present	Member, Association of Atherosclerosis	
18	1999 – Present	Member, Association for Medical Education in Europe	



19	1996 - 1997	Member of Interparliamentary Group for coordinating	
		Healthcare Systems development in Caucasian	
		Region, Azerbaijan, Armenia, Georgia	
20	1994 – Present	Member, Association of Georgian Physicians, Tbilisi,	
		Georgia	

Additional information
Optionally you can specify additional